Gilead resubmits new HIV drug Lenacapavir marketing application
- Moderna Latest Study: mRNA Therapy for Treating T Cell-Mediated Autoimmune Diseases
- The Biosecure Act May Hurt Pharmaceutical Supply Chains
- Mosquito Elimination on Global Health: Unraveling the Claim of 700K Annual Deaths
- Intensive Blood Pressure Management to Below 140 mmHg Reduces Stroke Risk, Regardless of Medication Dosage
- GLP-1 Drugs: How Significant is Their Impact on Brain Health?
- Why Eel Sashimi Is Unsafe: Understanding the Risks of Consuming Raw Eel
Gilead resubmits new HIV drug Lenacapavir marketing application
- Shocking! All existing AIDS vaccine developments have failed
- Sanofi Japan Data Breach: 730000 Healthcare Professionals’ Information Exposed
- CT Radiation Exposure Linked to Blood Cancer in Children and Adolescents
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
Gilead resubmits new HIV drug Lenacapavir marketing application, requiring only two doses per year
On June 27 , Gilead announced that it had resubmitted to the U.S. Food and Drug Administration (FDA) its development of a long-acting HIV-1 capsid inhibitor, Lenacapavir, for the treatment of severe multidrug-resistant (MDR) HIV-1 infection. (HTE) New Drug Application (NDA) for HIV-1 infection in patients .
If eventually approved, Lenacapavir would be the first and only HIV-1 regimen to be administered twice a year.
This time, Gilead resubmitted the NDA for Lenacapavir .
In February 2022 , the FDA issued a Complete Response Letter ( CRL ) questioning the Chemical Manufacturing and Control ( CMC ) issue of the borosilicate glass vial’s compatibility with Lenacapavir injectable solution .
The NDA resubmission contains comprehensive CMC data to support the compatibility of Lenacapavir with alternative vial types made of aluminosilicate glass.
In addition, the NDA is supported by extensive preclinical and early clinical study data and data from the Phase 2/3 CAPELLA study evaluating the antiviral activity of Lenacapavir administered subcutaneously every six months in combination with other antiretroviral drugs For persons with severe treatment experience with multidrug-resistant HIV-1 infection.
Once the NDA is accepted by the FDA , a new Prescription Drug User Fee Act (PDUFA) date will be set.
“Due to resistance to multiple antiretroviral therapies, some people living with HIV have very limited treatment options,” said Jared Baeten , MD, vice president of HIV clinical development at Gilead Sciences . “We are committed to addressing unmet needs and Recognize the urgency of filling critical treatment gaps for patients with multidrug-resistant HIV whose virus is no longer responsive to current treatments.”
Gilead resubmits new HIV drug Lenacapavir marketing application
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.
